The World Health Organization (WHO) panel, in its latest statement, has recommended against the use of the remdesivir, an antiviral drug, in hospitalized COVID-19 patients. WHO says there is no evidence that the drug improves mortality.
BREA, Calif., U.S.: Dental practices are struggling during the SARS-CoV-2 pandemic and so too are the companies that supply them with equipment and consumables. Envista Holdings cut its operating costs by more than $100 million (€84 million) between April and June and still posted an operating loss of close to $108 million. Staggering drops in earnings are the current reality for Envista and its competitors, but the dental giant said that recovery in dental markets is picking up pace.